RT Journal Article
SR Electronic
T1 A meta-analysis on the role of pre-existing chronic disease in the cardiac complications of SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.21.20136622
DO 10.1101/2020.06.21.20136622
A1 Sinclair, Jane E.
A1 Zhu, Yanshan
A1 Xu, Gang
A1 Ma, Wei
A1 Shi, Haiyan
A1 Ma, Kun-Long
A1 Cao, Chun-Feng
A1 Kong, Ling-Xi
A1 Wan, Ke-Qiang
A1 Liao, Juan
A1 Wang, Hai-Qiang
A1 Arentz, Matt
A1 Redd, Meredith
A1 Gallo, Linda A.
A1 Short, Kirsty R.
YR 2020
UL http://medrxiv.org/content/early/2020/12/10/2020.06.21.20136622.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with multiple direct and indirect cardiovascular complications. It is not yet well defined whether the patient groups at increased risk of SARS-CoV-2 severe respiratory disease experience similarly heightened incidence of cardiovascular complications. We sought to analyse the role of host co-morbidities (chronic respiratory illnesses, cardiovascular disease (CVD), hypertension or diabetes mellitus (DM)) in the acute cardiovascular complications associated with SARS-CoV-2 infection.Methods We retrospectively investigated published and pre-printed, publicly released, de-identified, data made available between Dec 1, 2019, and October 14, 2020. Information was accessed from PubMed, Embase, medRxiv and SSRN. 363 full-text articles were reviewed and 283 excluded for lack of original research, irrelevance to outcome, inappropriate cohort, or describing case reports of <10 patients. Data were extracted from 25 studies and the remaining 55 contacted to request appropriate data, to which four responded with data contributions. A final of 29 studies were included. This systematic review was conducted based on Preferred Reporting Items for Systematic Reviews (PRISMA) and Meta-analyses of Observational Studies in Epidemiology (MOOSE) statements. Included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS). Data were extracted independently by multiple observers. When I 2□<□50%, a fixed effects model was selected, while a random-effects model was employed when I 2□> 50%. Cardiovascular complications were measured as blood levels of cardiac biomarkers above the 99th percentile upper reference limit, new abnormalities in electrocardiography, and/or new abnormalities in echocardiography.Results Individual analyses of the majority of studies found that the median age was higher by approximately 10 years in patients with cardiovascular complications. Pooled analyses showed the development of SARS-CoV-2 cardiovascular complications was significantly increased in patients with chronic respiratory illness (Odds Ratio (OR) 1.67[1.48,1.88]), CVD (OR 3.37[2.57,4.43]), hypertension (OR 2.68[2.11,3.41]), DM (OR 1.60[1.31,1.95]) and male sex (OR 1.31[1.21,1.42]), findings that were mostly conserved during sub-analysis of studies stratified into four global geographic regions.Conclusions Age, chronic respiratory illness, CVD, hypertension, DM and male sex may represent prognostic factors for the development of both acute and chronic cardiovascular complications in COVID-19 disease, highlighting the need for a multidisciplinary approach to chronic disease patient management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKRS was supported by the Australian Research Council [DE180100512]. Collection of data contributed by Xu et al. was supported by the Guangzhou Health Research Project, the Guangzhou Health Committee (NO.20191A010014). The sponsors of this study had no role in the study design, collection, analysis, and interpretation of data, report writing, or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Ethics Research Office Cumbrae-Stewart Building #72 The University of Queensland St Lucia, QLD 4072 CRICOS PROVIDER NUMBER 00025B 2020001352 This project has been reviewed by the Office of Research Ethics and is deemed to be exempt from ethics review under the National Statement on Ethical Conduct in Human Research and University of Queensland policy, as research that uses only existing collections of data that contain only non-identifiable data about human beings AND is of negligible risk.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to this study has been included in the manuscript. Data contributed by Xu et al., Ma et al., and Arentz et al., may be obtained by contacting authors of each respective study. Data retrieved from remaining studies are published and publicly available.